News & Press review
Here you can find the latest news about Italfarmaco and the international press reviews.
2020 - June 25
As part of the measures to support the development of collaborations for the identification of therapies and diagnostic, protection and analysis systems to combat the Coronavirus emergency and other viral emergencies of the future, the Lombardy Region has financed the project "EPIgenetic Therapy for the treatment of COronavirus infections "- Acronym: EPICO
2019 - November 13
The “Journal of Medicinal Chemistry” publishes a paper on the identification of new and highly selective inhibitors of histone deacetylase 6 (HDAC6) by the Italfarmaco drug discovery team.
Corporate News
Please kindly note that you are leaving Italfarmaco Group website to connect to another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with current Italian legislation.
Press review
The material contained in this section is intended for informational purposes only and is not promotional. This section is intended for journalists and media.
2024 – March 21
Business Wire
Italfarmaco Receives FDA Approval for Duvyzat™ (givinostat) in Duchenne Muscular Dystrophy
March 21, 2024 - Business Wire
Please kindly note that you are leaving Italfarmaco Group website to connect to another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with the current Italian legislation.
2024 – March 19
Business Wire
Italfarmaco Publishes in The Lancet Neurology results from Phase 3 EPIDYS Study in Duchenne Muscular Dystrophy (DMD)
March 19, 2024 - Business Wire
Please kindly note that you are leaving Italfarmaco Group website to connect to another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with the current Italian legislation.
2023 – September 05
Business Wire
Italfarmaco Group Receives EMA Validation of Marketing Authorization Application for Givinostat in Duchenne Muscular Dystrophy
September 05, 2023 - Business Wire
Please kindly note that you are leaving Italfarmaco Group website to connect to another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with the current Italian legislation.
2023 – June 29
Business Wire
Italfarmaco Group Completes FDA Submission of New Drug Application for Givinostat in Duchenne Muscular Dystrophy and Receives Priority Review
June 29, 2023 - Business Wire
Please kindly note that you are leaving Italfarmaco Group website to connect to another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with the current Italian legislation.
2022 – June 25
Business Wire
Italfarmaco Group Announces Positive Topline Data from Phase 3 Trial Showing Beneficial Effect of Givinostat in Patients with Duchenne Muscular Dystrophy
June 25, 2022 - Business Wire
Please kindly note that you are leaving Italfarmaco Group website to connect to another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with the current Italian legislation.
Corporate Press
Please kindly note that you are leaving Italfarmaco Group website to connect to another website. The regulations and medical practices may differ from country to country and the information and data published on the website you are going to visit may not be compliant with current Italian legislation.